Drug
Elucirem
Elucirem: highest development phase Post-Market, developed by Guerbet. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Elucirem (Gadopiclenol) NCT05954559 | Post-Market | Myocardial Fibrosis |
| Elucirem NCT06057168 | Phase 3 | Brain Tumor, Primary |
Latest
No recent events.
Follow Elucirem on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.